Combination Vaccination and Broadly Neutralising Antibody Therapy in HIV

PHASE2RecruitingINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

September 5, 2025

Primary Completion Date

October 31, 2027

Study Completion Date

June 30, 2028

Conditions
HIV
Interventions
BIOLOGICAL

ChAdOx1.tHIVconsv1

solution for injection one dose of 2.5 x 10\^10 vp/ml Arm B and Arm C

BIOLOGICAL

ChAdOx1.HIVconsv62

solution for injection one dose of 2.5 x 10\^10 vp/ml Arm B and Arm C

BIOLOGICAL

MVA.tHIVconsv4

suspension for injection two doses of 1 x 10\^8 vpu/ml Arm B and Arm C

BIOLOGICAL

GS-5423

Solution for infusion 2550 mg Arm A, Arm B and Arm C

BIOLOGICAL

GS-2872

Solution for infusion 850 mg Arm A, Arm B and Arm C

OTHER

Treatment interruption induced viraemia

Participants pause ART before receiving vaccines and/or bNAbs Arm A and Arm C

Trial Locations (3)

SE1 7EH

NOT_YET_RECRUITING

Guys and St Thomas' NHS Trust, London

W2 1NY

NOT_YET_RECRUITING

St Mary's Clinical Trial Unit, London

OX3 7LJ

RECRUITING

Centre for Clinical Vaccinology and Tropical Medicine (CCVTM), Oxford

All Listed Sponsors
lead

University of Oxford

OTHER

NCT07054931 - Combination Vaccination and Broadly Neutralising Antibody Therapy in HIV | Biotech Hunter | Biotech Hunter